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Platinum(IV) compounds like oxoplatin (cis, cis, trans-diammine-dichlorido-dihydroxido-platinum(IV)) show increased stability
and therefore can be applied orally. In a panel of 38 human cancer cell lines this drug induced S-phase arrest and cell death
with IC50 values 2.5-fold higher than cisplatin. Oxoplatin may be converted to cisplatin by intracellular reducing agents, however,
exposure to 0.1M HCl mimicking gastric acid yielded cis-diammine-tetrachlorido-platinum(IV) exhibiting twofold increased
activity. Similar results were obtained for another platinum(IV) compound, JM 149 (ammine-dichlorido-(cyclohexylamine)-
dihydroxido-platinum(IV)), but not for its parent drug JM 216/satraplatin. Genome-wide expression proﬁling of H526 small cell
lung cancer cells treated with these platinum species revealed clear diﬀerences in the expression pattern of aﬀected genes between
oxoplatinandcisplatin.Inconclusion,oxoplatinconstitutesapotentoralagentthatiseitherreducedorconvertedtodistinctactive
compounds, for example, by gastric acid or acidic areas prevailing in solid tumors, in dependence of the respective pharmaceutical
formulation.
Copyright © 2009 Ulrike Olszewski et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Cisplatin (cis-diammine-dichlorido-platinum(II)) was est-
ablished as drug against diverse tumor types including
testicular, ovarian, head and neck, bladder, esophageal, and
small cell lung cancer (SCLC) [1, 2]. However, cisplatin
exhibits only limited activity against tumors like colon
and breast cancer and causes considerable side eﬀects, and
induction of resistance occurs frequently [3]. An auspicious
“second generation” of platinum(II)-based drugs introduced
into the clinic included carboplatin with similar cytotoxicity
b u tl e s ss i d ee ﬀects than cisplatin, and oxaliplatin with
antiproliferative eﬀects even in cancers insensitive to cis-
platin, for example, advanced colorectal tumors [4].
Platinum(II) drugs are known to act by direct binding
to deoxyguanosine and deoxyadenosine molecules of DNA
with formation of intrastrand crosslinks mainly and, to
a minor degree, mono- and interstrand adducts [5]. In
the recent years, several platinum analogs were developed,
for example, diamminecyclohexyl- or ethylenediammine-
analogs, nedaplatin, lobaplatin, ormaplatin, iproplatin as
well as photoactivable and polynuclear complexes, respec-
tively [6–11].
Molecules containing a platinum(IV) central atom pro-
vide several advantages over platinum(II) drugs, such as
increased kinetic inertness and reduced reactivity, resulting
in prolonged stability in the bloodstream, lower toxicity,
and eﬃcacy in cisplatin-resistant tumor cell lines [12,
13]. Due to their increased stability platinum(IV) com-
plexes may be furthermore suitable for oral application.
Distinct pharmacokinetic characteristics of new cytotoxic
platinum(IV) complexes are determined by diﬀerent axial
ligands [14]. For example, satraplatin (bis-acetato-ammine-
dichloro-cyclohexylamine-platinum(IV); JM 216), an orally
active analog of carboplatin, was one of the ﬁrst “third-
generation” agents that showed evidence of antitumor activ-
ity [15]. In a phase III trial that investigated satraplatin in
pretreated hormone-refractory prostate cancer patients the2 Metal-Based Drugs
drug improved end points, such as progression-free survival,
prostate-speciﬁc antigen response, and pain response, how-
ever, the diﬀerence in overall survival did not reach statistical
signiﬁcance [16].
New platinum(IV) compounds are under preclini-
cal development and show promising activity in vitro,
including trimethylplatinum(IV) complexes with cytosine
ligands, metallacrown ethers, and O,O
 -di-2-alkyl-(S,S)-
ethylenediamine-N,N
 -di-2-propanoate or ethylenediamine-
N,N
 -diacetatediesterligandsoftetrachlorido-platinum(IV)
complexes [17–20].
Since it is generally accepted that reduction of plat-
inum(IV) has to occur prior to binding to the target DNA,
platinum(IV) molecules are believed to represent relatively
stable prodrugs that are able to compass the tumor tissue
largely without being reduced in the bloodstream, enter the
cell, and reach their target intact [21–24]. Only following
reduction the resulting platinum(II) species bind to DNA
and inhibit replication and transcription by formation of
intra- and/or interstrand adducts resulting in cell cycle arrest
in the G2M phase and programmed cell death [13, 16].
Cellular reducing agents like ascorbic acid, thiol-containing
species like metallothioneins and glutathione, and others
may trigger an activation of platinum(IV) prodrugs [25].
A further orally applicable platinum(IV) anticancer drug
currently under development is cis, trans, cis-diammine-
dihydroxido-dichlorido-platinum(IV) (oxoplatin) which
was synthesized by Chugaev and Khlopin for the ﬁrst
time in the Russian Federation in 1927 [26]. Not until
1977, its cytotoxic activity was demonstrated in rat tumor
models [27]. Presnov et al. compared antitumoral and
pharmacokinetic properties of oxoplatin with that of
cisplatin: therapeutic and maximal tolerated doses (MTDs)
were tenfold higher for oxoplatin than for cisplatin.
Furthermore, oxoplatin exhibited a prolonged therapeutic
eﬀect, antimetastatic activity, and similar or even higher
tumor growth inhibition following eight days of either
intraperitoneal, intramuscular, subcutaneous, oral, or rectal
treatment. The MTD of perorally dispensed oxoplatin was
two times lower in comparison to all other administration
routes, and no complete cross-resistance was found for
cisplatin and oxoplatin. The absence of necrotic lesions
of the kidneys that are commonly observed for cisplatin
pointed to a much lower nephrotoxicity of oxoplatin. Finally,
oxoplatin left the blood-ﬂow much more rapidly than
cisplatin and showed signiﬁcantly shorter half-elimination
from blood than cisplatin. However, one study reported
signiﬁcant necrosis in the distal tubules of kidneys of rats
triggered by oxoplatin [28].
Native platinum(IV) compounds can bind to DNA
directly, however, this processis suchslow, that it is supposed
to be of no clinical relevance. Therefore in the present
paper the in vitro cytotoxicity of oxoplatin and its possible
activation by reduction through exposure to hydrochloric
a n da s c o r b i ca c i dw e r ei n v e s t i g a t e d .T h es t r u c t u r ea n d
pharmacokinetic characteristics of an orally applied drug
may be chemically modiﬁed during gastric passage. If the
compound is not inert, the result may be either activation or
inactivation by the prevailing acidic conditions in the stom-
ach. Since oxoplatin may represent a prodrug of cisplatin,
the intracellular eﬀects of both platinum drugs on gene
expression patterns of a sensitive cell line were compared
using microarrays for genome-wide expression analysis.
2.MaterialsandMethods
2.1. Chemical Reagents. Unless otherwise noted, all chemi-
cals were obtained from Sigma-Aldrich (St. Louis, Mo,
USA). Dulbecco’s phosphate buﬀered saline (PBS) was
purchased from Gibco/Invitrogen (Carlsbad,Calif,USA).
Oxoplatin (cis, cis, trans-diammine-dichlorido-dihydroxido-
platinum(IV)), trans-oxoplatin (trans, trans, trans-diamm-
ine-dichlorido-dihydroxido-platinum(IV)), cis-diammine-
tetrachlorido-platinum(IV), satraplatin (JM 216; bis-aceta-
to-ammine-dichlorido-cyclohexylamine-platinum(IV)), JM
149 (ammine-dichlorido-(cyclohexylamine)-dihydroxido-
platinum(IV)), and JM 118 (ammine-dichlorido-(cycloh-
exylamine)-platinum(II)) were synthesized according to sta-
ndard procedures by Chiracon, Luckenwalde, Germany,
and kindly provided by IPSS, Berlin, Germany
(Figure 1). All compounds were prepared as stock solu-
tions of 2mg/mL in either DMSO (cisplatin, cis-diamm-
inetetrachloroplatinum(IV)) or in 0.9% NaCl solution
sterilized by ﬁltration, and aliquots stored at −20◦C.
2.2. Derivatization of Oxoplatin. Solutions containing oxo-
platin at a concentration of 120μM were acidiﬁed to achieve
a ﬁnal concentration of 0.1M HCl, incubated at room tem-
perature for 15 minutes and ﬁnally pH was adjusted to pH =
7.4withNaOHfortheiruseinproliferationassays.Theputa-
tive derivate cis-diammine-tetrachloridoplatinum(IV) was
synthesized and served as reference substance for infrared
(IR) spectral analysis of the species resulting from addition
of 1.1g oxoplatin to 100mL 0.1M HCl, (37◦C, 120 minutes)
as well as for the in vitro experiments. The recorded IR
spectra of cis-diammine-tetrachloridoplatinum(IV) and of
the oxoplatin-HCl preparation proved to be undistinguish-
able (IR (λ[cm−1]): 3539 (w); 3334 (m); 3251 (s); 3174 (vs);
3075 (m); 2663 (w); 2624 (w); 2397 (w); 2189 (w); 1675
(m); 1556 (s); 1318 (s); 1309 (s); 1015 (w); 863 (w); 832
(w)) indicating conversion of the oxoplatin to cis-diammine-
tetrachloridoplatinum(IV). For reduction of oxoplatin the
compound was treated with ascorbic acid (5mM, 24 hours,
37◦C) prior to application.
2.3. Cell Lines and Culture Conditions. Cell lines were
obtained from American Type Culture Collection (ATCC,
Rockville, Md, USA), with the exception of melanoma cell
lines M518, M607, and JVSO (Department of Dermatol-
ogy, Medical University of Vienna) and the Ewing’s sar-
coma/PNET (peripheral neuroectodermal tumor) cell lines
(our institution and cooperations). Cells were grown RPMI-
1640 bicarbonate medium (Seromed, Berlin, Germany)
supplemented with 10% fetal bovine serum (Seromed) and
4mM glutamine in a humidiﬁed incubator (Heraeus Cytop-
erm, Hanau, Germany; 5% CO2,3 7 ◦C, 95% humidity). Cells
were checked for mycoplasma contamination (MycoplasmaMetal-Based Drugs 3
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Figure 1: Chemical structures of the platinum compounds used in the present study.
PCR ELISA, Roche Diagnostics, Vienna, Austria). Attached
cells were subcultured by trypsination (0.05% trypsin con-
taining 0.02% EDTA) two times a week. Cell numbers were
counted using a microcellcounter (CC110, Sysmex TOA,
Tokyo, Japan).
2.4. MTT Chemosensitivity Assay. 1 × 104 cells in 100μL
medium/well were distributed to 96 well microtiter plates
(Greiner, Kremsmuenster, Austria), and substances to be
tested were added in a volume of another 100μL. All
compounds were serially diluted in 6–10 twofold steps
in triplicate. The microtiter plates were incubated under
tissue culture conditions (RPMI-1640/10% FCS, 4mM
glutamine; 37◦C, 5% CO2, 95% humidity) for four days,
and cell viability was measured using a modiﬁed MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bro-
mide) assay (EZ4U, Biomedica, Vienna, Austria). This assay
quantiﬁes mitochondrial activity and thereby cell viability
by generation of formazane dye (optical density at 450nm)
from tetrazolium salts by mitochondrial reduction. Optical
density was measured in a microplate reader (Eurogenetics,
Brussels,Belgium)at450nmwithanemptywellasreference.
Test results for slowly and rapidly proliferating cells were
recorded between optical densities of 0.3 and 1.5, respec-
tively. Wells containing media alone were used as controls
and values obtained set to 100% proliferation.
2.5. Cell Cycle Analysis. 1 × 106 c e l l sw e r ec u l t i v a t e di n6 -
well plates and incubated with the compound of interest
for four days. Thereafter, cells were trypsinized, washed
in PBS, ﬁxed in 70% ethanol at −20◦Cf o r3 0m i n u t e s ,
washed again, transferred into staining solution (20μg/mL
propidium iodide (PI), 5μg/mL ribonuclease (RNase) A
and 0.05% Nonidet P40 in PBS), and incubated at room
temperature (RT) overnight. Washed cells were analyzed
by ﬂow cytometry (Cytomics FC500, Beckman Coulter,
Krefeld, Germany) at excitation and emission wavelengths
of 488 and 675nm, respectively, acquiring 1 × 104 cells per
run. MultiCycle AV software (Phoenix Flow Systems, San
Diego, Calif, USA) was employed for calculation of cell cycle
distribution from linear PI histograms. Percentages of cells
in cell cycle phases G1/0 (resting), S (DNA synthesis), and
G2M (mitotic cells) were recorded. Experiments were done
in duplicate.
2.6. Flow Cytometric Measurement of Reactive Oxygen Species.
Intracellular generation of reactive oxygen species (ROS)
induced by platinum compounds was measured by ﬂow
cytometry using dihydroethidium (DHE) for detection of
superoxide anion production. Treated and untreated cells
(0.5 × 106) in 6-well plates were incubated in RPMI-1640
medium containing 5μM DHE at 37◦C for 15 minutes. Dye
oxidation was quantiﬁed using ﬂow cytometry with excita-
tion and emission settings of 488 and 610nm, respectively.
2.7. Gene Expression Analysis. For gene expression analysis,
approximately 30 × 106 H 5 2 6S C L Cc e l l sw e r et r e a t e d
with 4.1μM cisplatin or 3.7μM oxoplatin, respectively, in
tissue culture ﬂasks for three days (37◦C, 5% CO2, 95%
humidity). In brief, cells were harvested by trypsination
and pellets of approximately 30 × 106 cells stored frozen
at –80◦C before they were extracted with 2.55mL extrac-
tion buﬀer (4M guanidine isothiocyanate, 0.5% sodium
N-lauroylsarcosinate, 10mM EDTA, 5mM sodium cit-
rate, 100μM β-mercaptoethanol) at 4◦C. DNA and RNA
of the lysates were separated by cesium triﬂuoroacetate
ultracentrifugation. RNA was washed with ice cold 96%
ethanol and dissolved in water in order to check for
content and purity by measurements of optical density
at 260/280nm. Gene expression analysis was performed
using the Applied Biosystems Human Genome Survey
Microarray V2.0 (Applied Biosystems, Foster City, Calif,
USA). Therefore, 2–5μg mRNA (20–50μgt o t a lR N A )w e r e
reversely transcribed to ﬁrst-strand cDNA and labeled
with digoxigenin-UTP according to the Applied Biosystems
Chemiluminescent Reverse Transcription protocol. RNA4 Metal-Based Drugs
was degraded and cDNA puriﬁed using DNA puriﬁca-
tion columns (Pico/Fresco—Heraeus, Hanau, Germany).
Hybridization of the cDNA and microarray analysis was
performed according to the Applied Biosystems Chemilu-
minescence Detection Kit protocol using a hybridization
oven (Infors HT Minitron, Bottmingen, Switzerland) for
incubation of the microarray cartridges and the Applied
Biosystems 1700 Chemiluminescent Microarray Analyzer for
evaluation. Results for oxoplatin- or cisplatin treatment were
then evaluated in comparison to the gene expression pattern
of H526 control cells using the Microsoft Excel software.
2.8. Statistics. Values are demonstrated as means ± SD.
StatisticalanalysiswasdoneusingStudent’st-testforsamples
with normal distribution (p<. 05 is regarded as statistical
signiﬁcant) or Kruskal-Wallis test as nonparametric method.
3. Results
3.1. Screening of the Antiproliferative Activity of Oxoplatin
in a Panel of Human Tumor Cell Lines. To investigate the
in vitro antiproliferative activity of oxoplatin a panel of 38
human cancer cell lines was initially screened by incubation
of cells with the compound at concentrations of 0.6–240μM
forfourdays.Oxoplatinexhibitedpartialactivitythroughout
the tumor entities tested. IC50 values ranged between 0.6–
120μMw i t ham e a nI C 50 of 22.8 ± 17.4μM for sensitive
cell lines deﬁned by an IC50 below 60μM( Figure 2). The
mean IC50 for cisplatin and the same sensitive cell lines
was 10.1 ± 9.1μM, respectively. The ovarian cancer cell
lines SK-OV3 and OVCAR3, and the renal cancer cell
lines Caki-I and A-498 were most insensitive, whereas each
of the remaining tumor entities included cell lines with
considerable sensitivity to oxoplatin.
3.2. Eﬀect of Pretreatment of the Platinum
Compounds with Acids
3.2.1. Activation of Oxoplatin by 0.1M HCl. In the follow-
ing experiments, dose-response curves were obtained for
oxoplatin, cisplatin, JM 216, and JM 149, either applied in
native form or following exposure to 0.1M HCl at room
temperature for 15 minutes, in proliferation assays using
COLO205cells.Concentrationsoftheplatinumcompounds
ranged from 0.6–120μM, and cells were incubated under
tissue culture conditions for four days.
The antiproliferative activity of cisplatin was not aﬀected
by 0.1M HCl, however, oxoplatin exhibited a twofold
enhanced cytotoxicity after preincubation under highly
acidic conditions. JM 216 was aﬀe c t e dt oam i n o rd e g r e e ,
whereas the activity of JM 149 was also markedly increased
(>8-fold) by exposure to 0.1M HCl. Figures 3(a) and 3(b)
showdose-responsecurvesofoxoplatin,JM216,andJM149,
with or without HCl-pretreatment, respectively. The trans-
acetato ligands of JM 216 protect against substitution by
0.1M HCl resulting in a dose-response curve similar to the
native drug. In contrast, the metabolite of JM 216 lacking
the trans-acetato groups, JM 149, exhibited pronounced
cytotoxic activity following activation by 0.1M HCl similar
to oxoplatin. The inactive stereoisomer trans-oxoplatin (all-
trans-diammine-dichlorido-dihydroxidoplatinum(IV)) was
not aﬀected by treatment with 0.1M HCl (data not shown).
Similar results regarding increases of the cytotoxicity of
oxoplatin by 0.1M HCl were obtained in a panel of other cell
lines (data not shown).
Exposure of 120μM oxoplatin to 6.3–100μMH C lp r i o r
to application to COLO 205 colon cancer and BxPC-3
pancreatic cancer cells revealed minimal concentrations of
12.5–25.0μM HCl to be required for activation of oxoplatin,
within an incubation time of 10 minutes.
The signiﬁcant enhancement of the cytotoxicity of
oxoplatin by 0.1M HCl strongly points to a chemical
modiﬁcationofthedrugatlowpH.Accordingly,comparison
of the anticancer activities of HCl-treated oxoplatin with
cis-diammine-tetrachloridoplatinum(IV) in chemosensitiv-
ity tests revealed no diﬀerences in cytotoxicity of the two
preparations (data not shown).
3.2.2. Activation of Oxoplatin by Physiological Concentrations
of Ascorbic Acid. Similar to the experiments using HCl
mentioned above, proliferation assays were carried out
where the platinum compounds were added to physiological
intracellular concentrations of ascorbic acid (5mM) prior
to application, and growth inhibition was compared to the
untreated drug. Dose-response curves of 3.75–120μMo x o -
platin following exposure to ascorbic acid revealed increased
antiproliferative activity of oxoplatin in COLO 205 cells
during four days of incubation (Figure 3(b)). The resulting
cytotoxicity was comparable to that of cisplatin. In addition,
pretreatment of oxoplatin with β-mercaptoethanol did not
leadtoanalterationoftheantiproliferativeeﬀectofoxoplatin
(data not shown).
3.3. Alterations in Cell Cycle Distribution Induced by Cisplatin
and Oxoplatin in Colo 205 Cells. To analyze alterations of
cell cycle distribution in COLO 205 colon cancer cells in
response to distinct platinum compounds concentrations of
the substances that had revealed similar cytotoxic activity
in previous proliferation assays were used. Thus, the eﬀects
of 65μM cisplatin, 120μM oxoplatin, and 120μM oxoplatin
treated with 0.1M HCl, respectively, were determined using
PI staining of DNA and ﬂow cytometry (Figure 4). In
comparison to cisplatin (accumulation of cells in S- and
mainly G2M-phase), oxoplatin induced partial arrest of cells
in G2M phase, while the residual cells remained in G1/0.
Interestingly, exposure of oxoplatin to 0.1M HCl prior to
addition to the cells resulted in cell cycle distribution with
pronouncedaccumulationofcellsinSandG2/Mphasesvery
similar to that of cisplatin. The same cell cycle pattern was
observed for cis-diammine-tetrachloridoplatinum(IV) (data
not shown).
3.4. Generation of ROS Triggered by Platinum Compounds.
Intracellular generation of ROS induced by platinum com-
pounds was measured by analysis of cells labeled with
dihydroethidium (DHE) by ﬂow cytometry. A comparison
of the potency of the induction of ROS-generation byMetal-Based Drugs 5
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Figure 2: In vitro cytotoxicity of oxoplatin against a panel of human cancer cell lines. Mean IC50 values for oxoplatin were obtained from
triplicate dose-response curves (sd < 8%). Cells were incubated under tissue culture conditions for four days and viable cells detected using
a modiﬁed MTT assay.
concentrations of the substances yielding similar cytotoxicity
revealed highest levels of ROS (Figure 5)b y2 0μMJ M2 1 6
(73.5 ± 1.5%), 65μM cisplatin (64.9 ± 0.3%), 0.1M HCl-
pre-exposed oxoplatin (58.9 ± 1.8%), and 120μM oxoplatin
(35.5 ± 3.0%). These results are in good agreement with the
increased cytotoxic activity of oxoplatin following treatment
with 0.1M HCl, however, the ROS-generating capacities of
JM216 and cisplatin correlate poorly with their respective
antitumor eﬀects, possibly due to diﬀerent intracellular
eﬀects and kinetics.
3.5. Comparative Microarray Gene Expression Analysis. As
shown in Figure 6, cisplatin and oxoplatin exhibited similar
antiproliferative eﬀects in the chemosensitive SCLC cell line
H526. This cell line is characterized by more rapid and
pronounced acidiﬁcation of the culture medium (pH < 6.8)
than other cell lines. These comparable IC50 concentra-
tions of cisplatin and oxoplatin point to an activation of
oxoplatin by chemical modiﬁcation involving the extracel-
lular/intracellular acidic conditions. Therefore H526 cells
were chosen to compare cisplatin- or oxoplatin-induced
alterations in genome-wide gene expression in cultures
treated with concentrations of the respective compound that
resulted in sublethal toxicity (>95% viability).
Of the 55 genes upregulated more than fourfold in
oxoplatin-treated H526 cells only three genes, namely,
HIST2H2BE, PNUTL2, and AKR1C3, were in common
with those genes upregulated in cisplatin-treated cells (the
27 genes exhibiting the strongest increases in expression
triggered by oxoplatin are shown in Table 1). In regard
to contrary gene expression, 2/55 genes were upregulated
in oxoplatin-treated and downregulated in cisplatin-treated
cells (RASD2, RASD family member 2; SAT, spermine N1-
acetyltransferase) and 0/150 genes under the reverse condi-
tions of up- and downregulation. Much more genes (73/302)
were downregulated both in oxoplatin-treated and cisplatin-
treated H526 cells (the 37 genes exhibiting the strongest
reduction in expression triggered by oxo- or cisplatin are
shown in Table 2). Cytotoxicity of oxoplatin was evidenced
by DNA damage-inducible genes, generation of ROS by dual
oxidase 2 (DUOX2), and cell death was most likely linked to
increased expression of caspase 3 (Table 1). Downregulated
genes common for oxoplatin and cisplatin include those
coding for antiapoptotic proteins (TNFRSF6B and BCL2L1)
as well as a number of genes associated with regulation of
thecytoskeletonandcellularmetabolism(Table 2).Although
oxoplatin and cisplatin showed a partial overlap of the
expression of aﬀected genes in H526 cells, almost 80% of
these genes were diﬀerent for the two drugs. This ﬁnding
strongly points to diﬀerent mechanisms of action of cisplatin
and oxoplatin that are not consistent with the role of
oxoplatin and derived species as inactive prodrugs of an
exclusively active cisplatin.
4. Discussion
Cisplatin has proved to be a potent cytotoxic agent in the
therapy of cancer [2]. In the last years, great importance
has been placed on the development of orally applicable
anticancer drugs in order to allow outpatient care. Among
the ﬁrst oral platinum coordination complexes established
are picoplatin and satraplatin that have shown promise in
preclinical and clinical trials [4]. Oral picoplatin is currently
being checked in a Phase-I study in patients with solid
tumors. Satraplatin (JM 216) showed promise in patients
withhormone-refractoryprostatecancerandwasconsidered
for approval by the Food and Drug Administration in 2007.
However, the satraplatin SPARC phase III trial in second-line
hormone refractory prostate cancer failed to improve overall
survival [16].6 Metal-Based Drugs
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Figure 3: Dose-response curves obtained in COLO 205 cells of (a) native oxoplatin and oxoplatin after incubation with 0.1M HCl for 15
minutes or 5mM ascorbic acid for 24 hours, and of (b) JM 216 or JM 149, respectively, also either as native compound or after exposure to
0.1M HCl for 15 minutes.
Oxoplatin represents another platinum(IV) compound
that may be administered orally. Pharmacokinetic studies
using 191Pt-labeled oxoplatin in melanoma B-16—bearing
mice showed rapid distribution throughout the blood and
most organs with a decline of the blood level after 1 hour
of intravenous drug administration. Elimination from the
blood followed a biexponential course with higher half-
lives in melanoma B-16—bearing mice than in controls
[29, 30]. The highest accumulation of oxoplatin was found
in kidneys, liver, spleen, adrenals, thymus, skin, and the
tumor, respectively. Since oxoplatin was rapidly excreted by
the kidneys it was regarded to possess only low nephro-
toxicity. Comparison of the pharmacokinetics of oxoplatin
and cisplatin revealed higher plasma levels of the former
following injection, and oxoplatin exhibited lower protein
binding. Oxoplatin was furthermore found to accumulate in
tumor tissue, and metabolization resulted in the formation
of several molecules, amongst them cisplatin pointing to the
role of oxoplatin being a prodrug of cisplatin, however, this
hypothesis has not been proved so far.
As shown in the present paper, oxoplatin exhibits cyto-
toxicity in a broader spectrum of tumor entities in vitro,
such as cancers of the colon, pancreas, breast, prostate asMetal-Based Drugs 7
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Figure 4: Comparison of cell cycle perturbations observed in COLO 205 colon cancer cells induced by the various platinum compounds
tested here. Cells were grown in (a) medium alone, (b) medium containing 65μM cisplatin, (c) 120μM oxoplatin, and (d) 120μM oxoplatin
following treatment with 0.1M HCl, respectively, under tissue culture conditions for four days, and subsequently stained with propidium
iodide (PI). The concentrations of the platinum compounds used had resulted in comparable cytotoxicity in preceding proliferation tests.
well as melanoma, tumors of childhood, and osteosarcoma
with IC50 levels ranging from 0.6–120μM. Still, the mech-
anism of action of platinum coordination complexes is not
fully understood. It is generally believed that platinum(IV)
compounds need to be reduced in order to bind to the
DNA, however, Novakova and others demonstrated that
platinum(IV) complexes can bind to DNA directly without
previous reduction, even though more slowly and to a
lesser extent than cisplatin [21–24, 31–34]. Cisplatin-DNA
adductsleadtoaconformationalchangeoftheDNAdouble-
helix allowing protein binding of molecules containing
high mobility group domains impairing DNA replication
and transcription [35–38]. Our results demonstrate that
o x o p l a t i ni n d u c e dc e l lc y c l ea r r e s ti nSa n dG 2 Mp h a s e s ,
generation of ROS, and cell death. In contrast, cisplatin led
to accumulation of cells mostly in G2M phase, indicating
diﬀerences in the modes of action of the two platinum com-
pounds. Furthermore, exposure of oxoplatin to 0.1M HCl
mimicking the low pH of gastric acid prior to application
to the cells yielded cell cycle arrest mainly in S-phase. In
comparison to that, the satraplatin metabolites JM 149 and
JM 118, representing cyclohexyl-substituted cis- or oxoplatin
analogs, triggered arrest mainly in S and G2M or G2M
phases, respectively, similar to cisplatin or oxoplatin (data
not shown).
Reduction of platinum(IV) compounds may take place
in the bloodstream or intracellularly and is accomplished by
reducing agents such as ascorbic acid, methionine, cysteine,
glutathione, uric or lactic acid, and sulfhydryl-group con-
taining proteins. For example, human serum albumin, the
predominant plasma protein mediating transport of drugs
and other (macro)molecules in the bloodstream, features8 Metal-Based Drugs
Table 1: Selected genes exhibiting > fourfold upregulated expression in H526 cells that were treated with oxoplatin assorted according to
their cellular function. H526 SCLC cells were either left untreated or treated with 3.75μM oxoplatin, respectively, in tissue culture ﬂasks
for three days. Thereafter, RNA of control and treated cells was extracted, and gene expression was analyzed using the Applied Biosystems
Human Genome Survey Microarray V2.0.
Cellular process Locus link Gene symbol Gene name
Transcription 2306 FOXD2 Forkhead box D2
5450 POU2AF1 POU domain, class 2, associating factor 1
1649 DDIT3 DNA-damage-inducible transcript 3
Apoptosis 84301 DDI2 DNA-damage inducible protein 2
9518 GDF15 Growth diﬀerentiation factor 15
836 CASP3 Caspase 3, apoptosis-related cysteine protease
8349 HIST2H2BE Histone 2, H2be
Cytoskeleton 649 BMP1 Bone morphogenetic protein 1
2620 GAS2 Growth arrest-speciﬁc 2
5414 PNUTL2 Peanut-like 2 (Drosophila)
5100 PCDH8 Protocadherin 8
Signal transduction 10673 TNFSF13B T u m o rn e c r o s i sf a c t o r( l i g a n d )s u p e r f a m i l y ,m e m b e r
13b
10368 CACNG3 Calcium channel, voltage-dependent, gamma subunit 3
8416 ANXA9 Annexin A9
1184 CLCN5 Chloride channel 5 (nephrolithiasis 2, X-linked, Dent
disease)
147798 TMC4 Transmembrane channel-like 4
Metabolism 50506 DUOX2 Dual oxidase 2
81894 SLC25A28 Solute carrier family 25, member 28
3067 HDC Histidine decarboxylase
8644 AKR1C3 Aldo-keto reductase family 1, member C3
6569 SLC34A1 Solute carrier family 34 (sodium phosphate), member 1
10404 PGCP Plasma glutamate carboxypeptidase
9709 HERPUD1 Homocysteine-inducible, endoplasmic reticulum
stress-inducible, ubiquitin-like domain member 1
6303 SAT Spermidine/spermine N1-acetyltransferase
Transport 1520 CTSS Cathepsin S
27074 LAMP3 Lysosomal-associated membrane protein 3
4189 DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9
reactive thiol groups of cysteine as well as methionine
residues, which may also constitute a binding partner for
platinum compounds [39, 40]. In contrast to a platinum(II)
analog, binding of platinum(IV) compounds to serum
albumin in vitro was reported to be very low and dependent
on the respective reduction potentials of the molecules
[12]. The axial ligands bound to the platinum(IV) center
determine reduction potential, stability under reducing
conditions as well as reactivity towards DNA-binding [12,
41]. These properties are conferred by the leaving groups
and decrease following the order chlorido > acetato >
hydroxido, implying that chlorido-substituents facilitate the
conversion of platinum(IV) into platinum(II) [42]. The
eﬀects of reducing agents on the activity of oxoplatin were
assessed in comparison to cisplatin in the present paper.
With respect to an oral drug, the normally very low
pH prevailing in the stomach that may be responsible for a
chemicalmodiﬁcationofthecompoundmustbeconsidered.
As a cell line relatively insensitive to oxoplatin but exhibiting
moderate sensitivity to cisplatin, COLO 205 colon cancer
cells were chosen to investigate a possible relevance of
highly acidic conditions on the potency of oxoplatin or
the other platinum(IV) compounds. Treatment of oxoplatin
with 0.1M HCl led to an approximately twofold increaseMetal-Based Drugs 9
Table 2: Selected genes exhibiting > fourfold commonly downregulated expression in H526 cells treated with oxoplatin or cisplatin
compared to untreated control cells classiﬁed according to their cellular function. For gene expression analysis H526 SCLC cells were treated
with 3.75μM oxoplatin or 4.1μM cisplatin, respectively, in tissue culture ﬂasks for three days. Thereafter, RNA of control and treated cells
was extracted, and gene expression was analyzed using Applied Biosystems Human Genome Survey Microarray V2.0.
Cellular process Locus link Gene symbol Gene name
Transcription 4150 MAZ MYC-associated zinc ﬁnger protein (purine-binding
transcription factor)
3221 HOXC4 Homeo box C4
10658 CUGBP1 CUG triplet repeat, RNA binding protein 1
Apoptosis 8771 TNFRSF6B Tumor necrosis factor receptor superfamily, member 6b,
decoy
598 BCL2L1 BCL2-like 1
3855 KRT7 Keratin 7
Cytoskeleton 347733 MGC8685 Tubulin, beta polypeptide paralog
823 CAPN1 Calpain 1, (mu/I) large subunit
50861 STMN3 Stathmin-like 3
5962 RDX Radixin
977 CD151 CD151 antigen
50512 PODLX2 Endoglycan
55920 TD-60 RCC1-like
91179 SCARF2 Scavenger receptor class F, member 2
6711 SPTBN1 Spectrin, beta, nonerythrocytic 1
6596 SMARCA3 SWI/SNF related, matrix associated, actin dependent
regulator of chromatin, subfamily a, member 3
4134 MAP4 Microtubule-associated protein 4
Signal transduction 51582 OAZIN Ornithine decarboxylase antizyme inhibitor
26469 PTPN18 Protein tyrosine phosphatase, nonreceptor type 18
(brain-derived)
11247 NXPH4 Neurexophilin 4
53944 CSNK1G1 Casein kinase 1, gamma 1
1445 CSK C-src tyrosine kinase
30851 TIP-1 Tax interaction protein 1
23187 PHLDB1 Pleckstrin homology-like domain, family B, member 1
3597 IL13RA1 Interleukin 13 receptor, alpha 1
Metabolism 2539 G6PD Glucose-6-phosphate dehydrogenase
5211 PFKL Phosphofructokinase, liver
2542 SLC37A4 Solute carrier family 37 (glycerol-6-phosphate transporter),
member 4
478 ATP1A3 ATPase, Na+/K+ transporting, alpha 3 polypeptide
55611 OTUB1 OTU domain, ubiquitin aldehyde binding 1
2030 SLC29A1 Solute carrier family 29 (nucleoside transporters), member
1
6566 SLC16A1 solute carrier family 16 (monocarboxylic acid transporters),
member 1
Transport 29924 EPN1 Epsin 1
6844 VAMP2 Vesicle-associated membrane protein 2 (synaptobrevin 2)
10527 IPO7 Importin 7
7514 XPO1 Exportin 1 (CRM1 homolog, yeast)
1654 DDX3X DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked10 Metal-Based Drugs
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Figure 5: Platinum compound-induced generation of ROS in
COLO 205 cells. Cells were treated with the respective platinum
compound for four days and labeled with DHE for detection of
superoxide production by ﬂow cytometry. Data are represented as
mean ± SD, n = 3.
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Figure 6: Dose-response curves of cisplatin and oxoplatin obtained
in H526 SCLC cells (mean ± SD, n = 3). H526 cells were chosen
for comparative microarray gene expression analysis, since the two
platinum compounds exhibited similar cytotoxicity, especially in
this cell line.
in the cytotoxicity that was comparable to that of cisplatin.
Cisplatin did not exhibit altered activity following treatment
with HCl. Administered orally, JM 216 is metabolized into
JM149andJM118exhibitingcytotoxiceﬀectsforthemselves
following the order JM 118 > JM 216 > JM 149 [16]. JM 118
was inert to 0.1M HCl, as was JM 216, however, JM 149, the
compound analogous to oxoplatin, revealed a considerably
increased cytotoxicity. Therefore the fate and activity of the
oral prodrug oxoplatin critically depend on its formulation,
that can be chosen to allow for release in the stomach
or part of the intestine. To ﬁgure out whether oxoplatin
was actually transformed into the putative derivate cis-
diammine-tetrachlorido-platinum(IV), this molecule was
synthesized and compared to 0.1M HCl-treated oxoplatin.
Cis-diammine-tetrachlorido-platinum(IV) yielded the same
cytotoxic eﬀect as HCl-treated oxoplatin and was proved to
be identical in IR spectroscopy. Due to the high reduction
potential of the chloride-ligands, it may be hypothesized that
those may be easily removed and the molecule converted
into platinum(II), however, as will be explained below, some
further ﬁndings point to diﬀerent mechanisms of action of
cisplatin and oxoplatin.
Cisplatin and oxoplatin exhibited similar antiprolifera-
tive eﬀects in the H526 cell line that was found to acidify
the extracellular medium to a signiﬁcant degree (pH <
6.8). Therefore, chemosensitive H526 cells were selected for
genome-wide microarray analysis of cisplatin- or oxoplatin-
induced gene expression. According to the ATCC, the H526
cell line, initiated using a bone metastasis of SCLC prior to
therapy, shows expression of neuron-speciﬁc enolase, brain
enzyme of creatine kinase, and p53 mRNA. This line pro-
ducescoloniesinsoftagarandtumorsinathymicnudemice.
Comparison of the gene expression patterns of controls and
treated cells revealed signiﬁcant diﬀerences in the expression
pattern of target genes for the two platinum compounds,
with only three upregulated genes in common. Approxi-
mately one fourth of the downregulated genes are shared
between oxoplatin- and cisplatin-treated H526 cells pointing
to common pathways in the suppression of genes involved in
platinum-induced cell death. Therefore the mode of action
ofoxoplatininvolvesamajorityofuniqueaﬀectedgenes,that
are clearly diﬀerent from those altered by cisplatin.
5. Conclusion
In summary, oxoplatin exhibits in vitro activity against
diverse human tumor cells, inducing growth arrest, gener-
ation of ROS and cell death. Depending on its formula-
t i o nt h i sd r u gi sc o n v e r t e dt ocis-diammine-tetrachlorido-
platinum(IV) under acidic conditions or reduced in the
presence of ascorbic acid. Comparative genome-wide gene
expression analysis using a chemosensitive SCLC cell line
demonstrates that the majority of the oxoplatin- and
cisplatin-regulated target genes are not identical and there-
fore oxoplatin represents not a simple prodrug of cisplatin.
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